組換え型抗血友病因子世界市場の発展状況と動向 2024-2030
英文タイトル: Global Recombinant Antihemophilic Factor Market Insights, Forecast to 2030
販売価格(消費税別)
個人版
マルチユーザー版
企業版
価格表記: USDを日本円(税抜)に換算,本日の銀行送金レート: 1USD=156.8円。
※米ドル表示価格+10%消費税。
価格表記: USDを日本円(税抜)に換算,本日の銀行送金レート: 1USD=156.8円。
※米ドル表示価格+10%消費税。
サンプルお申込み
お問い合わせ
※ご注文方法:お問い合わせフォームまたはメールにてご連絡ください。
支払方法:「銀行振込」の場合, 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期:原則として、受注後2~4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8~10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。
概要
本報告書は、組換え型抗血友病因子の世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別に組換え型抗血友病因子市場を分類しています。本レポートでは世界の組換え型抗血友病因子市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は:Takeda、Bayer、CSL、Pfizer、Biogen、Octapharma、Novo Nordisk、Sanofi、Sobi
レポートは組換え型抗血友病因子の主要生産者を調査し、主要地域や国の消費状況も提供します。組換え型抗血友病因子の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。
2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。タイプ別市場セグメント:
一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別(地域レベル、国レベル)の組換え型抗血友病因子生産量、成長率、市場シェアを調査している。
200IU
250IU
用途別の市場セグメント:
Hospital
Pharmacy
本レポートの詳細内容
本レポートは、世界の組換え型抗血友病因子市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて組換え型抗血友病因子市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
二. 消費面では、組換え型抗血友病因子の売上高を地域別(地域レベル・国レベル)、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。
三.主要メーカーの組換え型抗血友病因子売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の組換え型抗血友病因子市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。
四.本組換え型抗血友病因子のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。
章の概要第1章:組換え型抗血友病因子のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー(タイプ別およびアプリケーション別など)を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。(2019~2030)
第2章: 組換え型抗血友病因子の世界と主要生産者(地域/国)の生産/アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。(2019~2030)
第3章:世界、地域、国レベルにおける組換え型抗血友病因子の売上(消費)、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。(2019~2030)
第4章組換え型抗血友病因子メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。(2019~2024)
第5章:組換え型抗血友病因子の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。(2019~2030)
第6章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。(2019~2030)
第7章:北米(米国・カナダ):タイプ別、用途別、国別、セグメント別の売上高、収益。(2019~2030)
第8章:ヨーロッパ:タイプ別、用途別、国別、セグメント別の売上高と収益。(2019~2030)
第9章:中国:タイプ別、アプリケーション別、セグメント別の売上高、収益。(2019~2030)
第10章:アジア(中国を除く):タイプ別、用途別、地域別、セグメント別の売上高、収益。(2019~2030)
第11章:中東、アフリカ、中南米:タイプ別、用途別、国別、セグメント別の売上高、収益。(2019~2030)
第12章:組換え型抗血友病因子の主要メーカーの概要を提供し、製品の説明と仕様、組換え型抗血友病因子の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。(2019~2024)
第13章:産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章:組換え型抗血友病因子の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章:レポートの要点と結論。
概要
Recombinant antihemophilic factor works by temporarily raising levels of factor VIII in the blood to aid in clotting. The global Recombinant Antihemophilic Factor market is projected to grow from US$ 2260 million in 2024 to US$ 2994.2 million by 2030, at a Compound Annual Growth Rate (CAGR) of 4.8% during the forecast period. The market for recombinant antihemophilic factor has witnessed significant growth in recent years. This can be attributed to several factors, including the increasing prevalence of hemophilia, advancements in recombinant DNA technology, and improved access to healthcare services. Hemophilia is a genetic bleeding disorder that requires lifelong treatment with antihemophilic factors, such as factor VIII or factor IX. Recombinant antihemophilic factor, produced using recombinant DNA technology, offers advantages over plasma-derived products, including enhanced safety, reduced risk of infection transmission, and increased supply stability. Report Covers: This report presents an overview of global market for Recombinant Antihemophilic Factor, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. This report researches the key producers of Recombinant Antihemophilic Factor, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Recombinant Antihemophilic Factor, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries. This report focuses on the Recombinant Antihemophilic Factor sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Recombinant Antihemophilic Factor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way. This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Recombinant Antihemophilic Factor sales, projected growth trends, production technology, application and end-user industry. Descriptive company profiles of the major global players, including Takeda, Bayer, CSL, Pfizer, Biogen, Octapharma, Novo Nordisk, Sanofi and Sobi, etc. Market Segmentation By Company Takeda Bayer CSL Pfizer Biogen Octapharma Novo Nordisk Sanofi Sobi Segment by Type 200IU 250IU Segment by Application Hospital Pharmacy Segment by Region US & Canada U.S. Canada China Asia (excluding China) Japan South Korea China Taiwan Southeast Asia India Europe Germany France UK Italy Russia Latin America, Middle East & Africa Brazil Mexico Turkey Israel GCC Countries Chapter Outline Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term. Chapter 2: Sales (consumption), revenue of Recombinant Antihemophilic Factor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. Chapter 3: Detailed analysis of Recombinant Antihemophilic Factor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc. Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment. Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment. Chapter 8: China by Type, and by Application, sales, and revenue for each segment. Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment. Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment. Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Antihemophilic Factor sales, revenue, price, gross margin, and recent development, etc. Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers. Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 14: The main points and conclusions of the report.
総目録
1 Study Coverage
1.1 Recombinant Antihemophilic Factor Product Introduction
1.2 Market by Type
1.2.1 Global Recombinant Antihemophilic Factor Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 200IU
1.2.3 250IU
1.3 Market by Application
1.3.1 Global Recombinant Antihemophilic Factor Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Recombinant Antihemophilic Factor Sales Estimates and Forecasts 2019-2030
2.2 Global Recombinant Antihemophilic Factor Revenue by Region
2.2.1 Global Recombinant Antihemophilic Factor Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Recombinant Antihemophilic Factor Revenue by Region (2019-2024)
2.2.3 Global Recombinant Antihemophilic Factor Revenue by Region (2025-2030)
2.2.4 Global Recombinant Antihemophilic Factor Revenue Market Share by Region (2019-2030)
2.3 Global Recombinant Antihemophilic Factor Sales Estimates and Forecasts 2019-2030
2.4 Global Recombinant Antihemophilic Factor Sales by Region
2.4.1 Global Recombinant Antihemophilic Factor Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Recombinant Antihemophilic Factor Sales by Region (2019-2024)
2.4.3 Global Recombinant Antihemophilic Factor Sales by Region (2025-2030)
2.4.4 Global Recombinant Antihemophilic Factor Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Recombinant Antihemophilic Factor Sales by Manufacturers
3.1.1 Global Recombinant Antihemophilic Factor Sales by Manufacturers (2019-2024)
3.1.2 Global Recombinant Antihemophilic Factor Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Antihemophilic Factor in 2023
3.2 Global Recombinant Antihemophilic Factor Revenue by Manufacturers
3.2.1 Global Recombinant Antihemophilic Factor Revenue by Manufacturers (2019-2024)
3.2.2 Global Recombinant Antihemophilic Factor Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Recombinant Antihemophilic Factor Revenue in 2023
3.3 Global Key Players of Recombinant Antihemophilic Factor, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Recombinant Antihemophilic Factor Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Recombinant Antihemophilic Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Recombinant Antihemophilic Factor, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Recombinant Antihemophilic Factor, Product Offered and Application
3.8 Global Key Manufacturers of Recombinant Antihemophilic Factor, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Recombinant Antihemophilic Factor Sales by Type
4.1.1 Global Recombinant Antihemophilic Factor Historical Sales by Type (2019-2024)
4.1.2 Global Recombinant Antihemophilic Factor Forecasted Sales by Type (2025-2030)
4.1.3 Global Recombinant Antihemophilic Factor Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Antihemophilic Factor Revenue by Type
4.2.1 Global Recombinant Antihemophilic Factor Historical Revenue by Type (2019-2024)
4.2.2 Global Recombinant Antihemophilic Factor Forecasted Revenue by Type (2025-2030)
4.2.3 Global Recombinant Antihemophilic Factor Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Antihemophilic Factor Price by Type
4.3.1 Global Recombinant Antihemophilic Factor Price by Type (2019-2024)
4.3.2 Global Recombinant Antihemophilic Factor Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Recombinant Antihemophilic Factor Sales by Application
5.1.1 Global Recombinant Antihemophilic Factor Historical Sales by Application (2019-2024)
5.1.2 Global Recombinant Antihemophilic Factor Forecasted Sales by Application (2025-2030)
5.1.3 Global Recombinant Antihemophilic Factor Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Antihemophilic Factor Revenue by Application
5.2.1 Global Recombinant Antihemophilic Factor Historical Revenue by Application (2019-2024)
5.2.2 Global Recombinant Antihemophilic Factor Forecasted Revenue by Application (2025-2030)
5.2.3 Global Recombinant Antihemophilic Factor Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Antihemophilic Factor Price by Application
5.3.1 Global Recombinant Antihemophilic Factor Price by Application (2019-2024)
5.3.2 Global Recombinant Antihemophilic Factor Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Recombinant Antihemophilic Factor Market Size by Type
6.1.1 US & Canada Recombinant Antihemophilic Factor Sales by Type (2019-2030)
6.1.2 US & Canada Recombinant Antihemophilic Factor Revenue by Type (2019-2030)
6.2 US & Canada Recombinant Antihemophilic Factor Market Size by Application
6.2.1 US & Canada Recombinant Antihemophilic Factor Sales by Application (2019-2030)
6.2.2 US & Canada Recombinant Antihemophilic Factor Revenue by Application (2019-2030)
6.3 US & Canada Recombinant Antihemophilic Factor Market Size by Country
6.3.1 US & Canada Recombinant Antihemophilic Factor Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Recombinant Antihemophilic Factor Sales by Country (2019-2030)
6.3.3 US & Canada Recombinant Antihemophilic Factor Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Recombinant Antihemophilic Factor Market Size by Type
7.1.1 Europe Recombinant Antihemophilic Factor Sales by Type (2019-2030)
7.1.2 Europe Recombinant Antihemophilic Factor Revenue by Type (2019-2030)
7.2 Europe Recombinant Antihemophilic Factor Market Size by Application
7.2.1 Europe Recombinant Antihemophilic Factor Sales by Application (2019-2030)
7.2.2 Europe Recombinant Antihemophilic Factor Revenue by Application (2019-2030)
7.3 Europe Recombinant Antihemophilic Factor Market Size by Country
7.3.1 Europe Recombinant Antihemophilic Factor Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Recombinant Antihemophilic Factor Sales by Country (2019-2030)
7.3.3 Europe Recombinant Antihemophilic Factor Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 UK
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Recombinant Antihemophilic Factor Market Size
8.1.1 China Recombinant Antihemophilic Factor Sales (2019-2030)
8.1.2 China Recombinant Antihemophilic Factor Revenue (2019-2030)
8.2 China Recombinant Antihemophilic Factor Market Size by Application
8.2.1 China Recombinant Antihemophilic Factor Sales by Application (2019-2030)
8.2.2 China Recombinant Antihemophilic Factor Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Recombinant Antihemophilic Factor Market Size by Type
9.1.1 Asia Recombinant Antihemophilic Factor Sales by Type (2019-2030)
9.1.2 Asia Recombinant Antihemophilic Factor Revenue by Type (2019-2030)
9.2 Asia Recombinant Antihemophilic Factor Market Size by Application
9.2.1 Asia Recombinant Antihemophilic Factor Sales by Application (2019-2030)
9.2.2 Asia Recombinant Antihemophilic Factor Revenue by Application (2019-2030)
9.3 Asia Recombinant Antihemophilic Factor Sales by Region
9.3.1 Asia Recombinant Antihemophilic Factor Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Recombinant Antihemophilic Factor Revenue by Region (2019-2030)
9.3.3 Asia Recombinant Antihemophilic Factor Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Market Size by Type
10.1.1 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Market Size by Application
10.2.1 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Country
10.3.1 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Takeda
11.1.1 Takeda Company Information
11.1.2 Takeda Overview
11.1.3 Takeda Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Takeda Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Takeda Recent Developments
11.2 Bayer
11.2.1 Bayer Company Information
11.2.2 Bayer Overview
11.2.3 Bayer Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Bayer Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bayer Recent Developments
11.3 CSL
11.3.1 CSL Company Information
11.3.2 CSL Overview
11.3.3 CSL Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 CSL Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 CSL Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Pfizer Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Pfizer Recent Developments
11.5 Biogen
11.5.1 Biogen Company Information
11.5.2 Biogen Overview
11.5.3 Biogen Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Biogen Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Biogen Recent Developments
11.6 Octapharma
11.6.1 Octapharma Company Information
11.6.2 Octapharma Overview
11.6.3 Octapharma Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Octapharma Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Octapharma Recent Developments
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Information
11.7.2 Novo Nordisk Overview
11.7.3 Novo Nordisk Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Novo Nordisk Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Novo Nordisk Recent Developments
11.8 Sanofi
11.8.1 Sanofi Company Information
11.8.2 Sanofi Overview
11.8.3 Sanofi Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Sanofi Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Sanofi Recent Developments
11.9 Sobi
11.9.1 Sobi Company Information
11.9.2 Sobi Overview
11.9.3 Sobi Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Sobi Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Sobi Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Recombinant Antihemophilic Factor Industry Chain Analysis
12.2 Recombinant Antihemophilic Factor Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Recombinant Antihemophilic Factor Production Mode & Process
12.4 Recombinant Antihemophilic Factor Sales and Marketing
12.4.1 Recombinant Antihemophilic Factor Sales Channels
12.4.2 Recombinant Antihemophilic Factor Distributors
12.5 Recombinant Antihemophilic Factor Customers
13 Market Dynamics
13.1 Recombinant Antihemophilic Factor Industry Trends
13.2 Recombinant Antihemophilic Factor Market Drivers
13.3 Recombinant Antihemophilic Factor Market Challenges
13.4 Recombinant Antihemophilic Factor Market Restraints
14 Key Findings in The Global Recombinant Antihemophilic Factor Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
表と図のリスト
List of Tables Table 1. Global Recombinant Antihemophilic Factor Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million) Table 2. Major Manufacturers of 200IU Table 3. Major Manufacturers of 250IU Table 4. Global Recombinant Antihemophilic Factor Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million) Table 5. Global Recombinant Antihemophilic Factor Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million) Table 6. Global Recombinant Antihemophilic Factor Revenue by Region (2019-2024) & (US$ Million) Table 7. Global Recombinant Antihemophilic Factor Revenue by Region (2025-2030) & (US$ Million) Table 8. Global Recombinant Antihemophilic Factor Revenue Market Share by Region (2019-2024) Table 9. Global Recombinant Antihemophilic Factor Revenue Market Share by Region (2025-2030) Table 10. Global Recombinant Antihemophilic Factor Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million) Table 11. Global Recombinant Antihemophilic Factor Sales by Region (2019-2024) & (K Units) Table 12. Global Recombinant Antihemophilic Factor Sales by Region (2025-2030) & (K Units) Table 13. Global Recombinant Antihemophilic Factor Sales Market Share by Region (2019-2024) Table 14. Global Recombinant Antihemophilic Factor Sales Market Share by Region (2025-2030) Table 15. Global Recombinant Antihemophilic Factor Sales by Manufacturers (2019-2024) & (K Units) Table 16. Global Recombinant Antihemophilic Factor Sales Share by Manufacturers (2019-2024) Table 17. Global Recombinant Antihemophilic Factor Revenue by Manufacturers (2019-2024) & (US$ Million) Table 18. Global Recombinant Antihemophilic Factor Revenue Share by Manufacturers (2019-2024) Table 19. Global Key Players of Recombinant Antihemophilic Factor, Industry Ranking, 2022 VS 2023 VS 2024 Table 20. Recombinant Antihemophilic Factor Price by Manufacturers 2019-2024 (USD/Unit) Table 21. Global Recombinant Antihemophilic Factor Manufacturers Market Concentration Ratio (CR5 and HHI) Table 22. Global Recombinant Antihemophilic Factor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Antihemophilic Factor as of 2023) Table 23. Global Key Manufacturers of Recombinant Antihemophilic Factor, Manufacturing Base Distribution and Headquarters Table 24. Global Key Manufacturers of Recombinant Antihemophilic Factor, Product Offered and Application Table 25. Global Key Manufacturers of Recombinant Antihemophilic Factor, Date of Enter into This Industry Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global Recombinant Antihemophilic Factor Sales by Type (2019-2024) & (K Units) Table 28. Global Recombinant Antihemophilic Factor Sales by Type (2025-2030) & (K Units) Table 29. Global Recombinant Antihemophilic Factor Sales Share by Type (2019-2024) Table 30. Global Recombinant Antihemophilic Factor Sales Share by Type (2025-2030) Table 31. Global Recombinant Antihemophilic Factor Revenue by Type (2019-2024) & (US$ Million) Table 32. Global Recombinant Antihemophilic Factor Revenue by Type (2025-2030) & (US$ Million) Table 33. Global Recombinant Antihemophilic Factor Revenue Share by Type (2019-2024) Table 34. Global Recombinant Antihemophilic Factor Revenue Share by Type (2025-2030) Table 35. Recombinant Antihemophilic Factor Price by Type (2019-2024) & (USD/Unit) Table 36. Global Recombinant Antihemophilic Factor Price Forecast by Type (2025-2030) & (USD/Unit) Table 37. Global Recombinant Antihemophilic Factor Sales by Application (2019-2024) & (K Units) Table 38. Global Recombinant Antihemophilic Factor Sales by Application (2025-2030) & (K Units) Table 39. Global Recombinant Antihemophilic Factor Sales Share by Application (2019-2024) Table 40. Global Recombinant Antihemophilic Factor Sales Share by Application (2025-2030) Table 41. Global Recombinant Antihemophilic Factor Revenue by Application (2019-2024) & (US$ Million) Table 42. Global Recombinant Antihemophilic Factor Revenue by Application (2025-2030) & (US$ Million) Table 43. Global Recombinant Antihemophilic Factor Revenue Share by Application (2019-2024) Table 44. Global Recombinant Antihemophilic Factor Revenue Share by Application (2025-2030) Table 45. Recombinant Antihemophilic Factor Price by Application (2019-2024) & (USD/Unit) Table 46. Global Recombinant Antihemophilic Factor Price Forecast by Application (2025-2030) & (USD/Unit) Table 47. US & Canada Recombinant Antihemophilic Factor Sales by Type (2019-2024) & (K Units) Table 48. US & Canada Recombinant Antihemophilic Factor Sales by Type (2025-2030) & (K Units) Table 49. US & Canada Recombinant Antihemophilic Factor Revenue by Type (2019-2024) & (US$ Million) Table 50. US & Canada Recombinant Antihemophilic Factor Revenue by Type (2025-2030) & (US$ Million) Table 51. US & Canada Recombinant Antihemophilic Factor Sales by Application (2019-2024) & (K Units) Table 52. US & Canada Recombinant Antihemophilic Factor Sales by Application (2025-2030) & (K Units) Table 53. US & Canada Recombinant Antihemophilic Factor Revenue by Application (2019-2024) & (US$ Million) Table 54. US & Canada Recombinant Antihemophilic Factor Revenue by Application (2025-2030) & (US$ Million) Table 55. US & Canada Recombinant Antihemophilic Factor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million) Table 56. US & Canada Recombinant Antihemophilic Factor Revenue by Country (2019-2024) & (US$ Million) Table 57. US & Canada Recombinant Antihemophilic Factor Revenue by Country (2025-2030) & (US$ Million) Table 58. US & Canada Recombinant Antihemophilic Factor Sales by Country (2019-2024) & (K Units) Table 59. US & Canada Recombinant Antihemophilic Factor Sales by Country (2025-2030) & (K Units) Table 60. Europe Recombinant Antihemophilic Factor Sales by Type (2019-2024) & (K Units) Table 61. Europe Recombinant Antihemophilic Factor Sales by Type (2025-2030) & (K Units) Table 62. Europe Recombinant Antihemophilic Factor Revenue by Type (2019-2024) & (US$ Million) Table 63. Europe Recombinant Antihemophilic Factor Revenue by Type (2025-2030) & (US$ Million) Table 64. Europe Recombinant Antihemophilic Factor Sales by Application (2019-2024) & (K Units) Table 65. Europe Recombinant Antihemophilic Factor Sales by Application (2025-2030) & (K Units) Table 66. Europe Recombinant Antihemophilic Factor Revenue by Application (2019-2024) & (US$ Million) Table 67. Europe Recombinant Antihemophilic Factor Revenue by Application (2025-2030) & (US$ Million) Table 68. Europe Recombinant Antihemophilic Factor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million) Table 69. Europe Recombinant Antihemophilic Factor Revenue by Country (2019-2024) & (US$ Million) Table 70. Europe Recombinant Antihemophilic Factor Revenue by Country (2025-2030) & (US$ Million) Table 71. Europe Recombinant Antihemophilic Factor Sales by Country (2019-2024) & (K Units) Table 72. Europe Recombinant Antihemophilic Factor Sales by Country (2025-2030) & (K Units) Table 73. China Recombinant Antihemophilic Factor Sales by Type (2019-2024) & (K Units) Table 74. China Recombinant Antihemophilic Factor Sales by Type (2025-2030) & (K Units) Table 75. China Recombinant Antihemophilic Factor Revenue by Type (2019-2024) & (US$ Million) Table 76. China Recombinant Antihemophilic Factor Revenue by Type (2025-2030) & (US$ Million) Table 77. China Recombinant Antihemophilic Factor Sales by Application (2019-2024) & (K Units) Table 78. China Recombinant Antihemophilic Factor Sales by Application (2025-2030) & (K Units) Table 79. China Recombinant Antihemophilic Factor Revenue by Application (2019-2024) & (US$ Million) Table 80. China Recombinant Antihemophilic Factor Revenue by Application (2025-2030) & (US$ Million) Table 81. Asia Recombinant Antihemophilic Factor Sales by Type (2019-2024) & (K Units) Table 82. Asia Recombinant Antihemophilic Factor Sales by Type (2025-2030) & (K Units) Table 83. Asia Recombinant Antihemophilic Factor Revenue by Type (2019-2024) & (US$ Million) Table 84. Asia Recombinant Antihemophilic Factor Revenue by Type (2025-2030) & (US$ Million) Table 85. Asia Recombinant Antihemophilic Factor Sales by Application (2019-2024) & (K Units) Table 86. Asia Recombinant Antihemophilic Factor Sales by Application (2025-2030) & (K Units) Table 87. Asia Recombinant Antihemophilic Factor Revenue by Application (2019-2024) & (US$ Million) Table 88. Asia Recombinant Antihemophilic Factor Revenue by Application (2025-2030) & (US$ Million) Table 89. Asia Recombinant Antihemophilic Factor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million) Table 90. Asia Recombinant Antihemophilic Factor Revenue by Region (2019-2024) & (US$ Million) Table 91. Asia Recombinant Antihemophilic Factor Revenue by Region (2025-2030) & (US$ Million) Table 92. Asia Recombinant Antihemophilic Factor Sales by Region (2019-2024) & (K Units) Table 93. Asia Recombinant Antihemophilic Factor Sales by Region (2025-2030) & (K Units) Table 94. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Type (2019-2024) & (K Units) Table 95. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Type (2025-2030) & (K Units) Table 96. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Type (2019-2024) & (US$ Million) Table 97. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Type (2025-2030) & (US$ Million) Table 98. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Application (2019-2024) & (K Units) Table 99. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Application (2025-2030) & (K Units) Table 100. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Application (2019-2024) & (US$ Million) Table 101. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Application (2025-2030) & (US$ Million) Table 102. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million) Table 103. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Country (2019-2024) & (US$ Million) Table 104. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Country (2025-2030) & (US$ Million) Table 105. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Country (2019-2024) & (K Units) Table 106. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Country (2025-2030) & (K Units) Table 107. Takeda Company Information Table 108. Takeda Description and Major Businesses Table 109. Takeda Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 110. Takeda Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications Table 111. Takeda Recent Developments Table 112. Bayer Company Information Table 113. Bayer Description and Major Businesses Table 114. Bayer Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 115. Bayer Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications Table 116. Bayer Recent Developments Table 117. CSL Company Information Table 118. CSL Description and Major Businesses Table 119. CSL Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 120. CSL Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications Table 121. CSL Recent Developments Table 122. Pfizer Company Information Table 123. Pfizer Description and Major Businesses Table 124. Pfizer Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 125. Pfizer Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications Table 126. Pfizer Recent Developments Table 127. Biogen Company Information Table 128. Biogen Description and Major Businesses Table 129. Biogen Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 130. Biogen Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications Table 131. Biogen Recent Developments Table 132. Octapharma Company Information Table 133. Octapharma Description and Major Businesses Table 134. Octapharma Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 135. Octapharma Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications Table 136. Octapharma Recent Developments Table 137. Novo Nordisk Company Information Table 138. Novo Nordisk Description and Major Businesses Table 139. Novo Nordisk Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 140. Novo Nordisk Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications Table 141. Novo Nordisk Recent Developments Table 142. Sanofi Company Information Table 143. Sanofi Description and Major Businesses Table 144. Sanofi Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 145. Sanofi Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications Table 146. Sanofi Recent Developments Table 147. Sobi Company Information Table 148. Sobi Description and Major Businesses Table 149. Sobi Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 150. Sobi Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications Table 151. Sobi Recent Developments Table 152. Key Raw Materials Lists Table 153. Raw Materials Key Suppliers Lists Table 154. Recombinant Antihemophilic Factor Distributors List Table 155. Recombinant Antihemophilic Factor Customers List Table 156. Recombinant Antihemophilic Factor Market Trends Table 157. Recombinant Antihemophilic Factor Market Drivers Table 158. Recombinant Antihemophilic Factor Market Challenges Table 159. Recombinant Antihemophilic Factor Market Restraints Table 160. Research Programs/Design for This Report Table 161. Key Data Information from Secondary Sources Table 162. Key Data Information from Primary Sources List of Figures Figure 1. Recombinant Antihemophilic Factor Product Picture Figure 2. Global Recombinant Antihemophilic Factor Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million) Figure 3. Global Recombinant Antihemophilic Factor Market Share by Type in 2023 & 2030 Figure 4. 200IU Product Picture Figure 5. 250IU Product Picture Figure 6. Global Recombinant Antihemophilic Factor Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million) Figure 7. Global Recombinant Antihemophilic Factor Market Share by Application in 2023 & 2030 Figure 8. Hospital Figure 9. Pharmacy Figure 10. Recombinant Antihemophilic Factor Report Years Considered Figure 11. Global Recombinant Antihemophilic Factor Revenue, (US$ Million), 2019 VS 2023 VS 2030 Figure 12. Global Recombinant Antihemophilic Factor Revenue 2019-2030 (US$ Million) Figure 13. Global Recombinant Antihemophilic Factor Revenue Market Share by Region in Percentage: 2023 Versus 2030 Figure 14. Global Recombinant Antihemophilic Factor Revenue Market Share by Region (2019-2030) Figure 15. Global Recombinant Antihemophilic Factor Sales 2019-2030 ((K Units) Figure 16. Global Recombinant Antihemophilic Factor Sales Market Share by Region (2019-2030) Figure 17. US & Canada Recombinant Antihemophilic Factor Sales YoY (2019-2030) & (K Units) Figure 18. US & Canada Recombinant Antihemophilic Factor Revenue YoY (2019-2030) & (US$ Million) Figure 19. Europe Recombinant Antihemophilic Factor Sales YoY (2019-2030) & (K Units) Figure 20. Europe Recombinant Antihemophilic Factor Revenue YoY (2019-2030) & (US$ Million) Figure 21. China Recombinant Antihemophilic Factor Sales YoY (2019-2030) & (K Units) Figure 22. China Recombinant Antihemophilic Factor Revenue YoY (2019-2030) & (US$ Million) Figure 23. Asia (excluding China) Recombinant Antihemophilic Factor Sales YoY (2019-2030) & (K Units) Figure 24. Asia (excluding China) Recombinant Antihemophilic Factor Revenue YoY (2019-2030) & (US$ Million) Figure 25. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales YoY (2019-2030) & (K Units) Figure 26. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue YoY (2019-2030) & (US$ Million) Figure 27. The Recombinant Antihemophilic Factor Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023 Figure 28. The Top 5 and 10 Largest Manufacturers of Recombinant Antihemophilic Factor in the World: Market Share by Recombinant Antihemophilic Factor Revenue in 2023 Figure 29. Global Recombinant Antihemophilic Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023 Figure 30. Global Recombinant Antihemophilic Factor Sales Market Share by Type (2019-2030) Figure 31. Global Recombinant Antihemophilic Factor Revenue Market Share by Type (2019-2030) Figure 32. Global Recombinant Antihemophilic Factor Sales Market Share by Application (2019-2030) Figure 33. Global Recombinant Antihemophilic Factor Revenue Market Share by Application (2019-2030) Figure 34. US & Canada Recombinant Antihemophilic Factor Sales Market Share by Type (2019-2030) Figure 35. US & Canada Recombinant Antihemophilic Factor Revenue Market Share by Type (2019-2030) Figure 36. US & Canada Recombinant Antihemophilic Factor Sales Market Share by Application (2019-2030) Figure 37. US & Canada Recombinant Antihemophilic Factor Revenue Market Share by Application (2019-2030) Figure 38. US & Canada Recombinant Antihemophilic Factor Revenue Share by Country (2019-2030) Figure 39. US & Canada Recombinant Antihemophilic Factor Sales Share by Country (2019-2030) Figure 40. U.S. Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 41. Canada Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 42. Mexico Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 43. Europe Recombinant Antihemophilic Factor Sales Market Share by Type (2019-2030) Figure 44. Europe Recombinant Antihemophilic Factor Revenue Market Share by Type (2019-2030) Figure 45. Europe Recombinant Antihemophilic Factor Sales Market Share by Application (2019-2030) Figure 46. Europe Recombinant Antihemophilic Factor Revenue Market Share by Application (2019-2030) Figure 47. Europe Recombinant Antihemophilic Factor Revenue Share by Country (2019-2030) Figure 48. Europe Recombinant Antihemophilic Factor Sales Share by Country (2019-2030) Figure 49. Germany Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 50. France Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 51. UK Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 52. Italy Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 53. Russia Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 54. China Recombinant Antihemophilic Factor Sales Market Share by Type (2019-2030) Figure 55. China Recombinant Antihemophilic Factor Revenue Market Share by Type (2019-2030) Figure 56. China Recombinant Antihemophilic Factor Sales Market Share by Application (2019-2030) Figure 57. China Recombinant Antihemophilic Factor Revenue Market Share by Application (2019-2030) Figure 58. Asia Recombinant Antihemophilic Factor Sales Market Share by Type (2019-2030) Figure 59. Asia Recombinant Antihemophilic Factor Revenue Market Share by Type (2019-2030) Figure 60. Asia Recombinant Antihemophilic Factor Sales Market Share by Application (2019-2030) Figure 61. Asia Recombinant Antihemophilic Factor Revenue Market Share by Application (2019-2030) Figure 62. Asia Recombinant Antihemophilic Factor Revenue Share by Region (2019-2030) Figure 63. Asia Recombinant Antihemophilic Factor Sales Share by Region (2019-2030) Figure 64. Japan Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 65. South Korea Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 66. China Taiwan Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 67. Southeast Asia Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 68. India Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 69. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales Market Share by Type (2019-2030) Figure 70. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue Market Share by Type (2019-2030) Figure 71. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales Market Share by Application (2019-2030) Figure 72. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue Market Share by Application (2019-2030) Figure 73. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue Share by Country (2019-2030) Figure 74. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales Share by Country (2019-2030) Figure 75. Brazil Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 76. Mexico Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 77. Turkey Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 78. Israel Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 79. GCC Countries Recombinant Antihemophilic Factor Revenue (2019-2030) & (US$ Million) Figure 80. Recombinant Antihemophilic Factor Value Chain Figure 81. Recombinant Antihemophilic Factor Production Process Figure 82. Channels of Distribution Figure 83. Distributors Profiles Figure 84. Bottom-up and Top-down Approaches for This Report Figure 85. Data Triangulation Figure 86. Key Executives Interviewed
01. サンプル提供
ご購入前にサンプル(英語、日本語)が提供可能。
02. カスタマイズサービス
レポートの一部をご購入可能;基本バージョンに加え、ご要望に応じたカスタム委託調査も提供可能。
03. プロフェッショナルな日本語翻訳
AI翻訳ではなく、プロフェッショナルな日本語翻訳をご提供。納期:英語は2-4営業日以内、日本語は8-10営業日以内。
04. 多言語コミュニケーション
日本語、英語、中国語、ヒンディー語、ドイツ語、韓国語、フランス語の7ヶ国語でコミュニケーションサービスをご提供。
05. お支払方法
銀行振込(納品後、ご請求書送付)。
06. アフターサービス
ご購入後、ご質問があれば、3ヵ月以内に無料でアナリストと直接的に連絡できる。
請求書払いの場合:
レポート選択
見積もり依頼
メールでのご注文
入手(英語版は2〜4営業日、日本語版は8〜10営業日)
決済(後払い)
クレジットカード決済の場合:
レポート選択
ウェブサイトでのご注文
決済
入手(英語版は2〜4営業日、日本語版は8〜10営業日)